Related Experiment Video

Updated: Apr 26, 2026

Pseudomonas aeruginosa Induced Lung Injury Model
07:24

Pseudomonas aeruginosa Induced Lung Injury Model

Published on: October 29, 2014

18.1K

Management of Pseudomonas aeruginosa pneumonia: one size does not fit all

Jordi Rello, Bárbara Borgatta, Leonel Lagunes

    Critical Care (London, England)
    |July 17, 2014
    PubMed

    Insights

    Pseudomonas aeruginosa ventilator-associated pneumonia (VAP) is deadly, often treated inadequately. New strategies, including anti-pseudomonal vaccines and tailored therapies based on virulence factors, are needed for better patient outcomes.

    Area of Science:

    • Infectious Diseases
    • Pulmonology
    • Vaccinology

    Background:

    • High mortality rates linked to Pseudomonas aeruginosa (PSA) ventilator-associated pneumonia (VAP).
    • Frequent inadequacy of initial empiric therapy for PSA-VAP.
    • Need for novel management strategies to improve patient outcomes.

    Purpose of the Study:

    • To discuss recent advances in the management of PSA-VAP.
    • To propose a new paradigm for tailored and optimal management of PSA-VAP.
    • To highlight the potential of anti-pseudomonal vaccines for prophylaxis.

    Main Methods:

    • Review of current literature on PSA-VAP management.
    • Analysis of PSA virulence factors and their role in disease phenotypes.
    • Discussion of immunomodulatory therapy for virulent strains.

    Main Results:

    • Identification of distinct PSA phenotypes based on virulence factor association.
    • Potential for adjunctive immunomodulatory therapy in managing virulent PSA strains.
    • Emerging evidence supporting the need for prophylactic anti-pseudomonal vaccines.

    Conclusions:

    • A shift in management paradigm is crucial for PSA-VAP.
    • Tailored therapeutic approaches considering virulence factors are essential.
    • Vaccine prophylaxis represents a promising strategy for at-risk patients.

    More Related Videos

    Long Term Chronic Pseudomonas aeruginosa Airway Infection in Mice15:43

    Long Term Chronic Pseudomonas aeruginosa Airway Infection in Mice

    Published on: March 17, 2014

    23.0K
    Use of Artificial Sputum Medium to Test Antibiotic Efficacy Against Pseudomonas aeruginosa in Conditions More Relevant to the Cystic Fibrosis Lung07:46

    Use of Artificial Sputum Medium to Test Antibiotic Efficacy Against Pseudomonas aeruginosa in Conditions More Relevant to the Cystic Fibrosis Lung

    Published on: June 5, 2012

    34.5K

    Related Concept Videos

    Pneumonia IV: Management01:28

    Pneumonia IV: Management

    The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
    Bacterial Pneumonia Treatment
    For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
    1.2K
    Pneumonia V: Nursing management and Prevention01:30

    Pneumonia V: Nursing management and Prevention

    Nursing management of pneumonia involves promoting airway patency, facilitating rest and conserving energy, encouraging fluid intake, maintaining nutrition, and educating patients.
    The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
    Enhance airway patency
    Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed....
    4.1K
    Atypical Pneumonia01:14

    Atypical Pneumonia

    Atypical pneumonia, often caused by Mycoplasma pneumoniae, is a form of pulmonary infection that differs from the classical presentation of bacterial pneumonia in both its cause and clinical symptoms. Mycoplasma pneumoniae is a pleomorphic bacterium notable for its lack of a rigid cell wall. This structural characteristic imparts resistance to beta-lactam antibiotics and significantly influences the bacterium’s behavior within the human host.Other pathogens responsible for the disease...
    79
    Acute Pyelonephritis II: Diagnostic Studies and Management01:28

    Acute Pyelonephritis II: Diagnostic Studies and Management

    Introduction:For diagnosing acute pyelonephritis, a comprehensive patient history is collected to identify symptoms such as dysuria, frequent or urgent urination, flank pain, or costovertebral angle (CVA) tenderness that may suggest a kidney infection.Physical ExaminationDuring the physical examination, CVA tenderness is assessed. This involves gentle percussion over the costovertebral angle, where tenderness often indicates a kidney infection.Diagnostic TestsUrinalysis: Used to identify white...
    832
    Chronic Obstructive Pulmonary Disease-V: Management01:29

    Chronic Obstructive Pulmonary Disease-V: Management

    Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
    Smoking Cessation
    3.3K
    Pneumonia I: Introduction01:29

    Pneumonia I: Introduction

    Pneumonia is an infection of the lower respiratory tract that leads to inflammation of the lung parenchyma, often resulting in the accumulation of inflammatory exudate in the alveoli and airways. Unlike the watery, low-protein fluid exudate in pulmonary edema, the exudate in this case is a thick fluid rich in immune cells, proteins, and debris produced during infection and inflammation.This impairs gas exchange and can lead to consolidation of lung tissue. The infection may be caused by a...
    20